FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	DVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Pizzie Nick (Last) (First) (Middle) C/O AXSOME THERAPEUTICS, INC. 22 CORTLANDT STREET, 16TH FLOOR						2. Issuer Name and Ticker or Trading Symbol Axsome Therapeutics, Inc. [AXSM] 3. Date of Earliest Transaction (Month/Day/Year) 03/04/2022							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) CHIEF FINANCIAL OFFICER					
(Street) NEW YORK NY 10007 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - Non-	Deriva	ative S	Sec	urities	s Ac	auired. Di	sposed o	f. or Bei	neficiall	v Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				2A. Deemed Execution Date,			3. Transactio	4. Securi	ties Acquire d Of (D) (Inst	ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported Transact	5. Amount of Securities I Beneficially		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Co	ansaction			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	ode V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$29.91	03/04/2022			A		77,872		(1)	03/03/2032	Common Stock	77,872	\$0.00	77,872	2	D		
Restricted Stock Units	(2)	03/04/2022			A		41,176		(3)	(3)	Common Stock	41,176	\$0.00	41,176	6	D		

Explanation of Responses:

- $1. \ The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 4, 2026.$
- 2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- 3. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

Remarks:

/s/ Nick Pizzie

03/08/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.